Intelligent Diabetes Management System with Enhanced Pharmaceutical Compositions

A synergistic system integrating advanced technologies with optimized pharmaceutical compositions for personalized diabetes management and treatment.

The original patent relates to a pharmaceutical composition comprising Canagliflozin, but it has limitations in terms of personalized treatment and real-time monitoring. The new inventive concept addresses these limitations by incorporating blockchain, IoT, AI, and biodegradable materials to create a more powerful and effective system.

The new inventive concept comprises a wearable device integrated with a blockchain-based data storage system, which collects and analyzes physiological data to provide personalized treatment recommendations based on the optimized pharmaceutical composition. The system also includes an AI-powered formulation optimization module, IoT-enabled sensors for real-time stability monitoring, and a 3D printing process for manufacturing pharmaceutical compositions with controlled release properties. Additionally, the system incorporates machine learning algorithms to predict pharmaceutical composition efficacy and a notification system for alerting users of any changes in composition stability.

The new inventive concept combines distinct technologies to create a novel system that is not obvious from the original patent. The integration of blockchain, IoT, AI, and biodegradable materials with optimized pharmaceutical compositions provides a unique solution for personalized diabetes management and treatment.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT sensors, or biodegradable materials. Variations of the system could also include integration with other healthcare systems, such as electronic health records or telemedicine platforms.

The inventive concept has significant commercial potential in the diabetes management and treatment market, with potential applications in personalized medicine, real-time monitoring, and pharmaceutical composition optimization. The target industries include pharmaceutical companies, healthcare providers, and medical device manufacturers.